[Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer]

Publication

[Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer]

Journal Paper/Review - Feb 1, 2006

Huober Jens, Jackisch C, Untch M, Möbus V, Wallwiener D, Kaufmann M, Minkwitz G

Citation

Huober J, Jackisch C, Untch M, Möbus V, Wallwiener D, Kaufmann M, Minkwitz G. [Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer]. Zentralblatt für Gynäkologie 2006; 128:30-7.

Type

Journal Paper/Review (Deutsch)

Journal

Zentralblatt für Gynäkologie 2006; 128

Publication Date

Feb 1, 2006

Issn Print

0044-4197

Pages

30-7

Brief description/objective

The results of four randomized international multicentric trials evaluating the therapeutic benefit of Herceptin in the adjuvant treatment of HER2-neu positive primary breast cancer have been reported. These reports showed that even after short term follow up one year of Herceptin resulted in improved disease free, metastases free and overall survival. Design and results of these four studies and the recommendations of national and international societies for the use of Herceptin in the adjuvant setting will be discussed.